Answers for RocketRed in correct formatAnswers for RocketRed
First of all PMC is a great company with smart management and an enviable track record. There is room for both of these companies as they do not compete.
RocketRed asked:
"whats management past history any resource discoveries or any buyouts???"
Craig Schneider
One of Craig's first companies that he worked for was Ultra Petroleum. The stock dropped from .95 to .45 before blasting through the stratosphere to a stunning pre split price of close to $200. Put another way, the market cap rose from around $3 million to close to $3 Billion!
Loyal investors were rewarded once again in 2006, as he was the cofounder of Magnum Uranium, which was taken over by Energy Fuels in 2009. Shareholders were once again exposed to another potential 1000% gain by 2011.
RocketRed said:
"can needs money
watch for pp coming"
True they will need money soon.
You said on the pmc board:
"well can was a software company with resource directors and can has same management today"
Not fair...CAN moved 2 world renowned scientists to Vancouver to run their lab...these are serious scientists with a remarkable track record going back 15 years
First of all:
-Novartis is a $211 Billion company
Teva is a $45 Billion company
Pfizer is a $183 Billion company
Now read below:
"Dr. Hossain's successful financial deals based on his drug discoveries over the last 15 years include:
15) 2004: Xenon, Novartis Enter $157M Deal For Obesity Compounds
16) 2006: Xenon and Takeda Announce $75M Agreement To Develop and Commercialize XEN401 for Pain
17) 2006: Xenon Enters Into Anemia Collaboration With Roche ($7 Million for Equity, and $44 Million From Research Funding)
18) 2012: Teva inks $376M deal on Xenon pain program
4) Dr. Tarek Mansour (Pfizer) was responsible for multiple FDA approved drugs, where the market value exceeded $1 billion. (Zeffix, Troxatyl, Bosulif, Neratinib and PFE384)
Dr. Hyder A. Khoja, Ph.D., M.Sc., A.Ag.
- Presented his work both in at federal government and academic institutions with authorship in over 18 peer-reviewed papers, primarily in genomics, plant physiology, and alternative energy.
-His work was also recognized and appeared in United Nations Food and Agriculture Organization (FAO) Environment and Natural Resources Management as a working paper for Algae-based Biofuels"
No other cannabis therapy company in North America comes close to these facts other than $1.5 Billion GWPH:
32) World renowned scientific team with multidisciplinary expertise? Check.
33) CSO who has a track record that developed several drugs over 15 years, generating over $500m in revenues? Check
34) Global organizations, governments, and big pharma companies that have previously benefitted from the teams research? Check.
35) Proprietary Cannabinoid Drug Design Platform? Check.
36) Tools to isolate and identify chemical compounds both quickly and effectively? Check.
37) In-house Breeding, Genetics and Cultivation division? Check.
38) Capable of developing compounds for therapies in months rather than years? Check.
39) Target specific diseases and conditions? Check.
40) Outsource early-stage research and trials to conserve capital? Check.
41) Fast Forward through Phase I, Phase II & Phase III quickly and inexpensively compared to traditional Pharma? Check
42) Competitive edge from companies that rely on third-parties to manufacture their treatments? Check
43) Fully-integrated operations to lower costs and increase quality? Check
44) Capable of commercializing therapies in a 1/3 the time of traditional drug development? Check.
45) Anaglous company with a $1.5b market cap? Check
46) Developing medicines for:
- Glaucoma
- Pain and Inflammation
- Orphan Diseases
- Metabolic Disease (Obesity, Diabetes)
- Cancers and Metabolic Diseases? Check.